Jun 30, 2024
A recent announcement by Discovery Therapeutics Caribe in Cleveland eases a major fear coming with a diabetes diagnosis: the fear of amputat
By Cheryl LaBash
In a welcome breakthrough on April 10, the U.S. Food and Drug Administration greenlighted the phase 3 study of Heberprot-P, a Cuban medicine developed by the Center for Genetic Engineering and Biotechnology (CIGB) that has been shown to reduce diabetic amputation by more than 70 percent.
Why did it take so long? The failure of the U.S. to normalize relations with the Republic of Cuba has forced even urgent health initiatives like this one to thread its way through an insidious web of laws, regulations, and executive orders that only apply to Cuba.
